Two benefits at a glance
The FDA highlighted the importance of this news with a special announcement, noting that this is the first approval of its kind
CagriSema submitted for FDA approval in December 2025 with expected approval in Q4 2026 or Q1 2027, meaning launch around mid-2027
Ketone bodies can be used by tissues throughout the body, especially the brain, as an alternative to glucose for generating cellular energy
HSS Journal the Musculoskeletal Journal of Hospital for Special Surgery, 21(4), 485495.
Clinical and preclinical studies have revealed that AKI is a complex systemic disease with effects on virtually every organ 2 , including the lung 3,4 , heart 5,6 , liver 7,8 , brain 9 , and intestine 10